GALAPAGOS and GILEAD have demonstrated victory over scleroderma
One of the worst prognoses among rheumatic diseases is diffuse cutaneous systemic scleroderma. Treatment options for this condition are extremely limited. In normal practice, immunosuppressants are used as basic therapy, but they are not effective enough, therefore, more effective drugs are needed.
A lot of experimental drugs have disappointed the developers. One of such drugs is a selective cannabinoid agonist receptor known as lenabazum by Corbus Pharmaceuticals, which failed the III phase trial last week. An experimental autotoxin inhibitor developed by GALAPAGOS and GILEAD has been successful in the IIa phase of ziritaxestat and is considered as a breakthrough, even though it is in the early stages of development. Ziritaxestat has two serious side effects that suppress the enthusiasm of clinicians.
In addition to ziritaxestat, the other scleroderma candidates with different mechanisms of action are evaluated in the study of various phases.